1Department of Internal Medicine, Menoufia University Faculty of Medicine, Shebin Elkom, Egypt.
2Department of Tropical Medicine, Menoufia University Faculty of Medicine, Shebin Elkom, Egypt.
Copyright © 2017 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.
Variable | IGC group (n=292) | NIGC group (n=86) | Control group (n=60) | |||
---|---|---|---|---|---|---|
Before DAAs therapy | 3 Months after therapy | Before DAAs therapy | 3 Months after therapy | Baseline | After 3 months | |
FPG, mg/dL | ||||||
Range | 105–252 | 85–186 | 108–248 | 110–249 | 108–245 | 107–248 |
Mean±SD | 184.5±27.9 | 136.5±22.5 | 179.9±25.6 | 181.2±25.9 | 178.1±24.3 | 180.1±26.2 |
HbA1c, % | ||||||
Range | 6.9–8.7 | 6.4–7.7 | 6.8–8.8 | 6.8–8.7 | 6.9–8.8 | 6.8–8.9 |
Mean±SD | 8.1±0.44 | 7.3±0.34 | 8.2±0.48 | 8.1±0.46 | 8.2±0.43 | 8.3±0.46 |
Variable | IGC group (n=292) | NIGC group (n=86) | P valuea |
---|---|---|---|
Age, yr | 53.25±4.6 | 52.34±4.9 | 0.113b |
BMI before therapy, kg/m2 | 27.76±2.7 | 27.24±2.98 | 0.130b |
BMI after therapy, kg/m2 | 27.74±2.8 | 27.25±3.0 | 0.156b |
Duration of T2DM, yr | 9.41±4.69 | 13.24±4.25 | 0.001b |
Sex | 0.632c | ||
Male | 141 (48.3) | 39 (45.3) | |
Female | 151 (51.7) | 47 (54.7) | |
Family history of T2DM | 0.001c | ||
Positive | 125 (42.8) | 58 (67.4) | |
Negative | 167 (57.2) | 28 (32.6) | |
Child-Pugh classification | 0.021c | ||
A | 254 (87.0) | 66 (76.7) | |
B | 38 (13.0) | 20 (23.3) |
Factor | B | P value | Odds ratio | 95% CI |
---|---|---|---|---|
Duration of T2DM (<7 years) | 0.479 | 0.000 | 2.452 | 1.335–4.504 |
Child-Pugh classification (child A) | 0.407 | 0.001 | 2.025 | 1.106–3.711 |
Family history of T2DM (negative) | 0.916 | 0.000 | 2.767 | 1.667–4.595 |
FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; IGC, improved glycemic control; DAA, direct-acting antiviral agent; NIGC, non-improved glycemic control; SD, standard deviation.
Values are presented as mean±standard deviation or number (%). IGC, improved glycemic control; NIGC, non-improved glycemic control; BMI, body mass index; T2DM, type 2 diabetes mellitus. aProbability of statistical test is significant if ≤0.05, b
CI, confidence interval; T2DM, type 2 diabetes mellitus.